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Abstract 17 
In this work a novel multi-microfluidic crystallization platform called MMicroCryGen is 18 
presented, offering a facile methodology for generating individual crystals for fast and easy 19 
screening for polymorphism and crystal habit of solid compounds. The MMicroCryGen device 20 
is capable of performing 8×10 cooling crystallization experiments in parallel using 8 disposable 21 
microcapillary film strips, each requiring less than 25 μL of solution. Compared to traditional 22 
microfluidic systems the MMicroCryGen platform does not require complex fluid handling, it 23 
can be directly integrated with a 96 wells microplate and it can also work in “dipstick” mode. 24 
The produced crystals can be safely and directly observed inside the capillaries with optical 25 
and spectroscopic techniques. The platform was validated by performing a number of 26 
independent experimental runs for: (1) polymorph and hydrate screening for ortho-27 
aminobenzoic acid, succinic acid and piroxicam; (2) co-crystal form screening for the p-28 
Toluenesulfonamide/triphenylphosphine oxide system; (3) studying the effect of o-toluic acid 29 
on ortho-aminobenzoic cooling crystallization (effect of structurally related additives). In all 30 
three cases, all known solid forms were identified with a single experiment using ∼200 μL of 31 
solvent and just few micrograms of solid material. The MMicroCryGen is simple to use, 32 
inexpensive and it provides increased flexibility compared to traditional crystallization 33 
techniques, being an effective new microfluidic solution for solid form screening for 34 
pharmaceutical, fine chemicals, food and agrochemical industries.  35 
  36 
Introduction 37 
Polymorphism is known as the ability of a compound to exist in more than one crystalline 38 
structure and is very common in the crystallization of active pharmaceutical ingredients (APIs) 39 
(1). Polymorph screening is therefore essential during the development of new drugs since the 40 
formation of the wrong polymorph can affect solubility, rate of dissolution and toxicity of the 41 
API (1-3). The discovery of possible polymorphic forms for newly synthesized compounds is 42 
usually done by running independent crystallization experiments in small, bench scale (1-100 43 
mL) crystallizers or via high-throughput devices based on arrays of wells, tubes or vials. This 44 
task requires a large number of steps and it is often difficult and expensive to automate because 45 
of the complex fluid handling involved (4, 5). Robotic liquid handling systems provided the 46 
mean to automate and increase throughput for screening of novel compounds in a drug 47 
discovery environment (6); however, the high cost of such systems means the technology is 48 
only accessible to few.  49 
In recent years microfluidic devices have been used to study several crystallization steps, 50 
including nucleation and growth (7-11), polymorphism (12-14) and co-crystal formation (15). 51 
Microfluidic technologies offer the possibility of running several experiments in parallel using 52 
small quantities of API, which is particularly important during the early stages of clinical trials 53 
when only small quantity of API is available. Nevertheless, current microfluidic devices still 54 
require interface to complex fluid handling (16). Furthermore, the extraction of crystals from 55 
the microfluidic channels for off-line analysis can also be problematic. 56 
Droplet-based devices are the most commonly used microfluidic tools for measuring nucleation 57 
rate, metastable zone width as well as solubility, and for the screening of polymorphs (7, 16-58 
21). The main advantage of using droplets for crystal formation is that a small volume of 59 
solution can be isolated in an easy way such as using a manual or electronic pipette (20), or by 60 
segmenting the solution flow with an immiscible liquid or gas in a microchannel (17-19). The 61 
supersaturation necessary to form crystals can then be generated by decrease the temperature 62 
of the droplets (7), adding an anti-solvent or a reactant (19) or via solvent evaporation (20). 63 
Each droplet can be considered as a single crystallizer allowing a systematic determination of 64 
the primary nucleation kinetic as well as an easier determination of the polymorphism of each 65 
crystal nucleated. Furthermore, the wells containing the droplets for evaporation-based devices 66 
can be chemically functionalized via self-assembled monolayers of specific organic 67 
compounds. In this way polymorphism can be controlled via templated heterogeneous 68 
nucleation (20, 21). Despite these advantages, the droplet-based devices that use micro-69 
channels to mix immiscible liquids require the use of external pumps, precise flow control for 70 
the mixing of the two immiscible phases and complex microchannel geometry. Additionally, 71 
in the case of evaporation-based microfluidics, a controlled atmosphere around the droplets is 72 
necessary for a slow and controlled removal of the solvent.  73 
Both cooling and anti-solvent crystallization processes have been conducted in microfluidic 74 
channels with precise control of both temperature and solute concentration (12). Because of 75 
the reduced amount of crystallizing material needed, microfluidic devices are particularly 76 
convenient for the study of expensive compounds such as proteins (22, 23), or for safe handling 77 
of toxic and/or carcinogenic compounds (16). Compared to larger scale crystallizers, 78 
microfluidic crystallizers provide a micro-environment with laminar only mixing conditions 79 
that enable the formation of high quality crystals, with defined habit and limited structural 80 
defects or amorphicity. Such crystals can easily be analysed via optical microscopy, vibrational 81 
spectroscopy and, in some cases X-ray diffraction (16). Microfluidic devices are also 82 
particularly suited for polymorph screening. In fact, the reduced volume and the absence of 83 
turbulent mixing promotes primary over secondary nucleation and favours the discovery of a 84 
larger number of polymorphs and co-crystals (13-16). Furthermore, in small volumes the 85 
nucleation and persistence of highly unstable polymorphs is more likely compared to large 86 
scale crystallizers (12-14, 16, 24). It is worth noticing that the rate of nucleation in small 87 
volumes is always slower than for large crystallizers, and the formation of crystals that are 88 
large enough to be analysed takes a longer time.  89 
Despite the evident advantages of microfluidics technologies, current devices remain 90 
expensive to produce at small scale, require bulky fluid handling equipment and present 91 
solvent-compatibility issues.  92 
In this work a novel multi-microfluidic platform for the generation of individual separated 93 
crystals (MMicroCryGen) that allows rapid and facile screening for polymorphism and crystal 94 
habit from a small sample volume is presented for the first time. In contrast to existent droplet-95 
based microfluidic devices for polymorph screening (17-20) the MMicroCryGen does not 96 
require external pumps as sample is loaded by capillary action (similar to a conventional 97 
‘dipstick’ test) and crystals are generated by cooling, with smoother control of the 98 
supersaturation during nucleation. 99 
The MMicroCryGen device shown in Figure 1a was specifically designed to perform multiple 100 
cooling crystallization experiments in parallel, with the option of real-time, in-situ observation 101 
of the crystals using optical or spectroscopic sensors. This platform can be used for the 102 
screening of hydrates, salts and co-crystals, which are often used as expedients to improve the 103 
rate of dissolution and solubility of an API, as well as to study the morphology of the crystals 104 
in different solvents. 105 
The main consumable of the MMicroCryGen is a set of multiplex, microfluidic strips obtained 106 
via cutting a longer MicroCapillary Film (MCF). The MCF is a flat film containing an array of 107 
ten parallel microcapillaries fabricated from fluorinated ethylene propylene co-polymer 108 
(Teflon-FEP®) using a novel continuous melt-extrusion process (25, 26). Photos of the MCF 109 
strips are shown in  Figure 1b and c. Due to the geometry and optical properties of FEP-110 
Teflon®, the microcapillaries are uniquely transparent in a very broad range of wavelengths 111 
including UV, VIS and NIR. Additionally, the MCF material is available in different inner 112 
internal diameters as reported elsewhere (27). Although FEP-Teflon® is naturally 113 
hydrophobic, internal coating of the microcapillaries with a hydrophilic hydrogel (28) enables 114 
the aspiration of fluid sample from a conventional microtiter plate by capillary action. Small 115 
volumes of API solutions (around 25 µL) can be prepared and aspirated into the 116 
microcapillaries without the use of pumps or syringes, similarly to conventional ‘dip stick’ 117 
tests. The small volume, low cost, transparency and hydrophilicity of the MCF material makes 118 
it an optimal consumable capillary element for the MMicroCryGen platform. The device uses 119 
a Peltier heat exchanger for carrying out controlled cooling crystallizations, enabling the study 120 
of both crystal morphology and polymorphism. In this work, the MMicroCryGen platform was 121 
validated by carrying out polymorph screening of succinic acid (SA) and ortho-aminobenzoic 122 
acid (OABA) (29-32), by determining the effect of o-toluic acid (OTA) on the polymorphism 123 
of OABA and by studying the formation of hydrates of piroxicam and co-crystals of p-124 
Toluenesulfonamide (p-TSA) and Triphenylphosphine oxide (TPPO) (33). The data presented 125 
show that the MMicroCryGen is a valuable microfluidic solution for facile polymorph 126 
screening of APIs since it requires a smaller amount of drugs and solvents and considerably 127 
less and cheaper additional instrumentation compared to standard techniques. The device can 128 
be particularly useful during the early stages of drug development when only a small amount 129 
of material is available and for the study of toxic, genotoxic or carcinogenic APIs. 130 
 131 
Experimental 132 
Materials 133 
For the screening experiments succinic acid (SA, from Sigma Aldrich, >99.0 % purity), ortho-134 
aminobenzoic acid (OABA, from Sigma Aldrich, purity >98%), piroxicam (from Hangzhou 135 
Hyper Chemicals Limited, 99 % purity, anhydrous), o-toluic acid, (OTA, from Sigma Aldrich, 136 
99% purity) and p-Toluenesulfonamide (p-TSA, 99 %) and triphenylphosphine oxide (TPPO, 137 
99 %) was sourced from Sigma-Aldrich (Dorset, UK) and used as received. Deionized water 138 
(Millipore ultrapure water system) isopropyl alcohol (IPA 99.97 % grade, Fisher Scientific, 139 
Loughborough, UK), acetone (Fisher Scientific, >99.98 % grade) and acetonitrile (Fisher 140 
Scientific, grade 99.9 %) were used as solvents.  141 
Multi-Microfluidic Crystal Generator (MMicroCryGen) 142 
Figure 2 shows the miniaturised MMicroCryGen device, developed and built in house at 143 
Loughborough University (UK). The main element is a re-usable frame (60.0 mm×78.8 mm, 144 
as shown in the drawings provided in the Supporting Information) composed of an aluminium 145 
plate, a central transparent Perspex cover and two side aluminium edges used for sealing the 146 
MCF strips and keeping them in a flat position (Figure 2a and 2d). The frame has 8 slots for 147 
the insertions of 70-80 mm long MCF strips. The slots are spaced by 6.11 mm centre-to-centre, 148 
enabling the direct interface with a 96 wells microplate (Figure 2d). Each MCF strip has an 149 
internal volume of approximately 25 μL and each 2.5 μL microcapillary can be considered as 150 
a single crystallizer with no mixing. Although the MMicroCryGen was operated manually, it 151 
offers the opportunity for easy automation with a robot arm, and does not require any fluid 152 
handling equipment/pumps. The MCF strips are kept in a flat position on the plate and sealed 153 
at both ends to avoid solvent evaporation by compressing the central Perspex cover and the 154 
two lateral aluminium edges with three sets of four screws. The lateral edges are provided with 155 
8 pointy protrusions that compress both edges of the MCF strips. Although in this work the 156 
whole frame was kept in position using three sets of screws (Figure 2b), the design could be 157 
further simplified with a one-step, ‘clip’ mechanism. The capillaries could be observed in real 158 
time through the Perspex cover using optical or spectroscopic sensors.  159 
The whole aluminium frame containing the MCF strips lay on a polyoxymethylene plate that 160 
contains a Peltier unit for temperature control (Meerstetter Engineering TEC-1090, Rubigen, 161 
Switzerland, shown in Figure 2b). The Peltier element (ThermaTECTM Series HT4, Laird 162 
Technologies, London United Kingdom) allows a range of temperatures in the microcapillaries 163 
between -20 and 120 °C and a maximum cooling rate of 5 °C/min. The Peltier unit is connected 164 
to a fan (BIG Shuriken 2, model SCBSK-2100 purchased from Scythe, Tokyo, Japan) and a 165 
controller (Meerstetter Engineering TEC-1091 running with TEC Service v3.0) for temperature 166 
regulation. Multiple units could be arranged in parallel and controlled independently for a 167 
higher number of simultaneous experiments. 168 
  169 
 170 
Fabrication of hydrophilic microfluidic, MCF strips  171 
The MCF material was manufactured by Lamina Dielectrics Ltd (Billingshurst, West Sussex, 172 
UK) from Teflon® FEP (Dupont, USA) and consists of an array of 10 parallel microcapillaries 173 
with a mean hydraulic diameter of 206 ± 12.6 μm (34). The raw MCF strips are hydrophobic 174 
(28), therefore they would require a pressure driven flow for sample loading; however in this 175 
work the MCF strips were made hydrophilic by coating the inside of each capillary with an 176 
hydrogel, poly(vinyl alcohol) (PVOH) (28). In this way the MCF strips could be filled simply 177 
by capillary action (‘dip stick’ mode). During the coating procedure 100 mL of an aqueous 178 
solution of PVOH (MW 13 000–23 000, >98 % hydrolysed from Sigma-Aldrich, Dorset, UK) 179 
with concentration of 5 mg/mL was recirculated through a 6 m long MCF at a flowrate of 50 180 
mL/h for 12-15 hrs using a FPLC P-500 Pharmacia Biotech (Piscataway, USA) pump and 181 
Upchurch flangeless tube fittings (Kinesis, Saint Neots, United Kingdom). After that, the 182 
PVOH coating was crosslinked with glutaraldehyde by manually filling the MCF strip with a 183 
freshly prepared solution of PVOH (5 mg/mL) containing 5 mM of glutaraldehyde (Sigma-184 
Aldrich, UK) and 5 mM HCl (Sigma-Aldrich, UK). The solution was kept inside the strips for 185 
2 hours at 37 °C, after which the MCF strips were manually washed and dried with air using a 186 
50 mL syringe (34). 187 
Solid form screening experiments in the MMicroCryGen platform 188 
For each experiment different solutions were prepared and loaded in the MMicroCryGen 189 
platform using the same procedure. The central Perspex cover was positioned on the aluminium 190 
frame and secured with four screws, then 8 hydrophilic or hydrophobic MCF strips of 70-80 191 
mm length were inserted in the slots. For hydrophilic strips, the frame was positioned vertically 192 
above a 96 wells microplate loaded with clear API solutions and then lowered in order to fully 193 
immerse the tip of each strip in the wells. For hydrophobic strips, the microcapillaries were 194 
aspirated using a multi-syringe aspiration device reported elsewhere (34). On both cases, after 195 
complete filling of the capillaries with solution, the frame was placed in horizontal position 196 
and the lateral aluminium edges were secured with 8 screws (4 at each side), automatically 197 
sealing both ends of the microcapillaries. The frame containing the MCF strips was then placed 198 
on the Peltier heat exchanger and the desired temperature or cooling profile set from the 199 
temperature control software. On-line monitoring of the experiments was performed with a 200 
USB Microscope (5.0 Megapixels supplied by MAOZUA, China). The MMicroCryGen device 201 
allows 80 independent parallel crystallization experiments in one go, this can be easily further 202 
expanded by increasing the number of strips.  203 
Once crystals were formed within the microcapillaries, the whole frame was removed from the 204 
Peltier unit and the MCF strips were individually analysed for crystal morphology and 205 
polymorphism. A Raman microscope DXR 780 nm (Thermo Scientific equipped with OMNIC 206 
8 software) equipped with a Linkam hot-stage was used to identify the structure of the crystals 207 
produced.  208 
For the polymorph screening experiments succinic acid (SA) and ortho-aminobenzoic acid 209 
(OABA) were used as solid compounds. Only deionized water was the solvent for succinic 210 
acid, while mixtures of deionized water and isopropyl alcohol were used for OABA. A solution 211 
of SA in water with concentration of 0.145 g/g solvent was prepared at 50 ⁰C and loaded in 212 
one row of a standard 96-wells microplate before being interfaced with the MMicroCryGen. 213 
The MCF strips were then cooled down to 5.0 °C at a rate of -0.5 °C/min. For OABA 214 
polymorph screening solutions at different concentrations of OABA were prepared and loaded 215 
into the capillaries at 60 °C, before being cooled down to 3.0 °C at a rate of -1.0 °C/min.  216 
Piroxicam in mixtures of deionized water and acetone was used in the hydrate screening 217 
experiments. Four solutions at different concentrations of piroxicam as well as solvent 218 
composition were prepared at 50 °C and loaded in duplicated MCF strips. The temperature was 219 
reduced to 3.0 °C at a rate of -1.0 °C/min.  220 
In the co-crystal screening experiments, p-Toluenesulfonamide and triphenylphosphine oxide 221 
were used with acetonitrile as solvent. Two solutions containing both components in specific 222 
stoichiometric ratios were prepared at 50.0 °C, and each loaded into four MCF strips. After 223 
that, the temperature was reduced to 3.0 °C at a rate of -1.0 °C/min.  224 
Finally, a set of experiments was conducted in the presence of o-toluic acid (OTA) in order to 225 
determine the effect of a structurally related additive on the crystallization of OABA. Four 226 
different aqueous solutions with concentration of OABA of 0.010 g/g water and different ratios 227 
OTA/OABA w/w were prepared at 50 ⁰C and loaded into the MCF strips. After that the 228 
temperature was reduced to 5.0 °C at a rate of -1.0 °C/min. 229 
In all experimental sets, the MMicroCryGen was further incubated overnight at 5.0 °C enabling 230 
full growth of crystals upon completion of the cooling stage.  231 
 232 
Results and discussion 233 
Polymorph screening of SA and OABA 234 
SA is known to have two polymorphic forms, α and β, which are enantiotropically related. The 235 
triclinic α-form is usually obtained by solid transformation from the β-form at temperatures 236 
above 137 °C while the monoclinic β-form is the polymorph that generally precipitates from 237 
water in various morphologies (29, 30). Microphotographs for SA crystals nucleated in the 238 
MMicroCryGen platform are shown in Figure 3b-3e, whereas Figure 3a shows plate-like 239 
crystals of β-form only nucleated from an aqueous solution of the same concentration in a 350 240 
mL vessel with overhead stirring (29). Both high aspect ratio needles and plate-like crystals 241 
were observed in the MCF strips. Raman spectroscopy analysis (Figure 4) confirmed the needle 242 
SA crystals were of α-form. The spectra of these crystals were also compared with those 243 
obtained from hot-stage experiments performed in the available Raman microscope. SA β-form 244 
crystals were heated up above the transition temperature of 137 ⁰C and then quickly cooled 245 
down to ambient temperature to allow the formation of the α-form on the hot-stage. 246 
Crystallisation in the MCF strips resulted in formation of SA crystals in their α-form, which is 247 
usually not observed in cooling crystallization in aqueous solutions. This is presumably due to 248 
both the reduced volume and the absence of convection and turbulent mixing in the 249 
microfluidic strips of the MMicroCryGen device. Such conditions promote primary over 250 
secondary nucleation, allowing the formation of a larger number of possible crystal structures, 251 
which is ideal for polymorph screening.  252 
 253 
The Raman spectra for both polymorphs of SA obtained in the MCF strips are shown in Figure 254 
4, and compared to the spectrum of an empty microcapillary. FEP-Teflon® has distinct, clear 255 
peaks that can be easily identified and subtracted from the total final spectra; strong intensity 256 
FEP-Teflon® peaks can be found at values of Raman shift of 290, 385, 730, 1225, 1300, 1380 257 
cm-1. Depending on the objective and the size of the analysed crystals, it is possible to focus 258 
the Raman laser on a single crystal, avoiding the signal from the MCF strip. Both hydrophilic 259 
and hydrophobic capillaries were tested and no differences were observed in respect to SA 260 
polymorph formation. In fact, both structures were always obtained, suggesting that the 261 
chemistry of the capillary’s inner surface did not have a templating effect on the nucleation of 262 
this compound. 263 
 264 
Polymorph screening in different solvent mixtures was performed with OABA. The solvent 265 
compositions and OABA concentrations for each MCF strip are summarised in Table 1. In 266 
contrast to OABA crystallisation experiments previously conducted at larger scale, where only 267 
form I and II could be precipitated in water/IPA mixtures (31), all three known polymorphs of 268 
OABA were obtained in the capillaries, similarly to what was observed with SA. It can also be 269 
noted that, due to the slower kinetics of nucleation in small volumes, some capillaries did not 270 
show any visible crystals in the time scale used for experiments (around 18-24 hrs). 271 
 272 
Table 1: Experimental conditions and results for polymorph screening of OABA. 273 
MCF strip 
number 
Solvent composition  
(% of IPA in water, w/w) 
OABA concentration 
(g/g solvent) 
Crystals nucleated in 
each MCF strip 
1 0 0.010 0 
2 2%  0.010 1 (form I) 
3 5% 0.010 0 
4 10%  0.015 0 
5 15%  0.020 2 (form II) 
6 20%  0.030 2 (form II) 5 (form III)  
7 25%  0.055 4 (form II) 2 (form III)  
8 30%  0.080 1 (form II) 3 (form III)  
 274 
The MMicroCryGen device allowed to identify all the three known forms of OABA from a 275 
small amount of material, demonstrating the advantage of using this novel methodology for 276 
polymorph screening. The area in the Raman spectrum that unequivocally identifies the three 277 
OABA polymorphs is between 1500 and 1700 cm-1 (Figure 5). Form I presents a peak at 1665 278 
cm-1 and a doublet at 1600 cm-1, form II has a strong peak at 1565 cm-1 and form III presents 279 
the same peak but shifted to 1560 cm-1. Finally, form III is characterized by a strong peak at 280 
1610 cm-1, which is not present in form I and it is weaker in form II. 281 
 282 
The polymorphs screening experiments performed in the MMicroCryGen platform show the 283 
advantage of using small volumes in the absence of mixing for the discovery of new crystal 284 
structure.   285 
Hydrate detection for Piroxicam 286 
Piroxicam was crystallized in different mixtures of acetone and water in order to identify the 287 
possible polymorphs and confirm the presence of hydrate forms. Table 2 shows the 288 
experimental conditions and the different polymorphs identified by Raman spectroscopy, all 289 
known polymorphs and the hydrate form (35-37) were detected in the microcapillaries. 290 
Microscopic images of the two polymorphs are shown in Figure 6b, with the thin needles 291 
characteristic of form II clearly distinguishable from the prismatic form I crystals. The 292 
monohydrate form of piroxicam was obtained in all solutions containing water. These crystals 293 
have a characteristic bright yellow colour as shown in Figure 6a.  294 
 295 
Table 2: Experimental conditions and results for polymorph screening of piroxicam. 296 
MCF strip 
number 
Solvent composition 
(% w/w) 
Concentration 
(g/g solvent) 
Crystals nucleated in each MCF 
strip 
1-2 100% acetone 0.040 Anhydrous form I and form II 
3-4 5% water in acetone 0.035 Anhydrous form II (needles) and 
monohydrate (prism) 
5-6 20% water in acetone 0.013 Piroxicam monohydrate 
7-8 30% water in acetone 0.009 Piroxicam monohydrate 
 297 
Raman spectroscopy was also used to distinguish among the polymorphs and the monohydrate 298 
form of piroxicam within the MCF strips. Figure 6c shows the region between 1500 and 1700 299 
cm-1, where the three forms can be identified without interference from the FEP-Teflon®. The 300 
monohydrate form is characterized by a single strong peak at 1590 cm-1, whereas form I has a 301 
high intensity peak at 1520 cm-1 and finally, form II is the only polymorph with a peak at 1540 302 
cm-1. 303 
 304 
In the case of piroxicam, the MMicroCryGen enabled simultaneous identification of the two 305 
known polymorphs and the hydrate form in a single experiment with four different solutions 306 
of piroxicam in acetone and water mixtures.  307 
Screening for co-crystals 308 
A further set of experiments was carried out aiming to demonstrate the application of the 309 
MMicroCryGen device to identify co-crystal structures, using p-Toluenesulfonamide (p-TSA) 310 
and Triphenylphosphine oxide (TPPO) as model compounds.  311 
 312 
Table 3: Experimental conditions and structures obtained during the screening of TSA/TPPO co-crystals. 313 
Solvent composition 
(% w/w) 
Concentration 
p-TSA 
(g/g solvent) 
Concentration 
TPPO  
(g/g solvent) 
Crystals nucleated in each MCF 
strip 
100% acetonitrile 0.02987 0.01492 3:2 co-crystal form 
100 % acetonitrile 0.01154 0.01489 1:1 co-crystal form 
 314 
The two co-crystals known for those chemicals, with molecular ratio p-TSA/TPPO 3:2 and 1:1 315 
(33), were quickly and successfully identified in a single experiment in the MMicroCryGen 316 
device, as confirmed by Raman spectroscopy according to data available from literature (33). 317 
Experimental conditions are described in Table 3, whereas the Raman spectra of the two co-318 
crystal forms obtained are shown in Figure 7. The Raman spectra for pure p-TSA and TPPO 319 
were compared to data available in literature (33, 38), confirming the formation of two co-320 
crystal forms. The characteristic regions of the Raman spectrum for the unequivocal 321 
identification of the two co-crystal forms are shown in Figure 7. Characteristic peaks for the 322 
1:1 co-crystal are located at 317, 460, 507, 934 and 1151 cm-1, whereas the 3:2 co-crystal is 323 
characterized by specific peaks at 310, 915 and 1149 cm-1(Figure 7). 324 
These experimental demonstrate the use of ‘dip stick’ microcapillaries for discovery of new 325 
co-crystal structures. Furthermore, the use of the MMicroCryGen platform allowed the 326 
identification of such co-crystal forms running a single experiment, with the use of limited 327 
amount of chemicals as well as solvents.  328 
 329 
Screening of the effect of additives on polymorphism 330 
Additives can have an effect on the polymorphic outcome of crystallization processes. These 331 
additives can act by inhibiting nucleation or growth of a certain polymorph of the main 332 
crystallizing compound, therefore stabilizing a different form. They can also stereo-selectively 333 
bind to specific surfaces of the targeted crystal nuclei, inhibiting their growth and therefore 334 
modifying the morphology of the crystals (32). The MMicroCryGen device was used to 335 
determine the effect of a structurally related additive (o-toluic acid, OTA) on the polymorphic 336 
outcome of OABA. Experiments at larger scale conducted with this compound and a similar 337 
molecule (benzoic acid) showed that a structurally related additive promoted nucleation of 338 
OABA form III, which can normally be obtained only by sublimation or polymorphic 339 
transformation at temperatures higher than the transition one (around 60 ⁰C) (32). Four aqueous 340 
solutions at different ratios OTA/OABA were loaded into the MCF strips before starting the 341 
cooling profile. Table 4 shows the polymorphs detected in the capillaries.  342 
 343 
Table 4: Polymorphic outcome of cooling crystallization of OABA in the presence of the structurally related 344 
molecule OTA. 345 
MCF strips 
number 
Ratio 
OTA/OABA 
w/w 
OABA polymorphs identified 
in MCF 
1-2 0 Form I and II 
3-4 5% Form I, Form II, Form III 
5-6 10% Form III 
7-8 15% Form III 
 346 
 347 
Similarly to previously reported observations at larger scale experiments with benzoic acid 348 
(32), the addition of a structurally related additive promotes the formation of OABA form III 349 
in water. In fact, only form I and II were nucleated in water in the absence of additive, whereas 350 
preferential nucleation of only form III could be observed at increasing concentrations of OTA. 351 
This indicates that, similarly to benzoic acid, OTA has an effect on the polymorphic outcome 352 
of OABA crystals generated via cooling. Crystallization experiments in the MMicroCryGen 353 
platform allowed easier determination of the effect of a structurally related additive on the 354 
crystallization of OABA using a considerably lower amount of solvent and materials compared 355 
to experiments conducted at larger scale (32). 356 
Conclusions 357 
The presented microfluidic MMicroCryGen crystallization device represents a valuable novel 358 
solution for polymorph and co-crystal screening of small molecules, requiring a smaller amount 359 
of compound and solvents and considerably fewer and cheaper fluidics and electronic 360 
instrumentation compared to standard microfluidic techniques, as well as larger scale 361 
equipment. The device and methodology proposed has the ability of enabling up to 80 parallel 362 
crystallization experiments without any pipetting or complex fluid handling, which could be 363 
particularly useful during the early stages of drug development when only a small amount of 364 
material is available, and for the study of particularly toxic, genotoxic or carcinogenic APIs. In 365 
this paper the MMicroCryGen platform was validated for solid form screening of SA, OABA, 366 
Piroxicam and the TSA/TPPO system. All known polymorphs, hydrates and co-crystals of the 367 
systems studied were identified with a reduced number of experiments and using very small 368 
amounts of material. The MMicroCryGen platform could also be used for more complex 369 
experiments including the study of the effect of additives on crystal forms resulting from 370 
cooling crystallization.  371 
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